# A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

> **NCT07401862** · PHASE1 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 36 (estimated)

## Conditions studied

- Hepatic Insufficiency

## Interventions

- **DRUG:** LY3841136

## Key facts

- **NCT ID:** NCT07401862
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-10
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07401862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07401862, "A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07401862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*